Iheezo (chloroprocaine ophthalmic) dosing, indications, interactions, adverse effects, and more

Sections

Sections chloroprocaine ophthalmic
Dosing & Uses
Adverse Effects
Warnings
Warnings
Pharmacology
Administration
Images
Patient Handout
Formulary

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

ophthalmic gel

3% (24mg chloroprocaine/800mg gel) as 1.25mL single-use vial

Ocular Surface Anesthesia

Topical gel indicated for ocular surface anesthesia

Apply 3 gtts topically to ocular surface in area of planned procedure

May reapply as needed to maintain anesthetic effect

Safety and efficacy not established

>10%

Mydriasis (26%)

Conjunctival hyperemia (11%)

1-10%

Eye irritation (6%)

Contraindications

History of hypersensitivity to product components

Cautions

Not for injection or intraocular administration

Corneal injury due to insensitivity may occur; instruct patients to not touch their eye(s) for at least 10-20 minutes after anesthetic applied to avoid accidental injuries

Prolonged use of topical ocular anesthetic may produce permanent corneal opacification and ulceration with accompanying visual loss

Do not touch dropper tip to any surface to avoid contaminating the gel

Indicated for administration under the direct supervision of a healthcare provider; not intended for patient self-administration

Pregnancy

There are no adequate and well-controlled studies regarding use in pregnant females to inform of a drug associated risk

There are no animal reproduction studies

Lactation

There are no data on presence of drug in human milk, effects on breastfed infants, or effects on milk production

Mechanism of Action

As with other local anesthetics, blocks generation and conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential

Progression of anesthesia is related to diameter, myelination, and conduction velocity of affected nerve fibers

Clinically, the order of loss of nerve function is as follows: (1) pain, (2) temperature, (3) touch, (4) proprioception, and (5) skeletal muscle tone

Absorption

Systemic exposure to chloroprocaine following topical ocular administration has not been studied

Metabolism

Metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues

Rapidly metabolized in plasma by hydrolysis of ester linkage by pseudocholinesterase; hydrolysis results in beta-diethylaminoethanol and 2-chloro-4-aminobenzoic acid, which inhibit sulfonamides action

Elimination

Half-life: ~25 seconds (adults); ~43 seconds (neonates)

Excretion: Mainly excreted by kidney; urinary excretion affected by urinary perfusion and factors affecting urinary pH

Ophthalmic Administration

For topical ophthalmic use

Do not inject or intraocularly administer

Discard after use

Storage

Store at 15-25ºC (59-77ºF)

Images

No images available for this drug.

Patient Handout

A Patient Handout is not currently available for this monograph.

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Create Your List of Plans

Adding plans allows you to:

View the formulary and any restrictions for each plan.
Manage and view all your plans together – even plans in different states.
Compare formulary status to other drugs in the same class.
Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

View explanations for tiers and restrictions

Tier	Description
1	This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2	This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC	NOT COVERED – Drugs that are not covered by the plan.

Code	Definition
PA	Prior Authorization Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL	Quantity Limits Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST	Step Therapy Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR	Other Restrictions Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.

Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.

[CLOSE WINDOW]

Sections chloroprocaine ophthalmic
Dosing & Uses
Adverse Effects
Warnings
Warnings
Pharmacology
Administration
Images
Patient Handout
Formulary

chloroprocaine ophthalmic (Rx)